| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/23/2024 | $22.00 | Overweight | Piper Sandler |
| 4/3/2024 | $37.00 | Buy | Craig Hallum |
| 7/13/2023 | $35.00 | Outperform | Northland Capital |
Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered second SUBLOCADE injection a week later vs. standard 28 days, enabling patients to achieve and maintain target medication levels more quickly.Presented at the 2024 Canadian Society of Addiction Medicine (CSAM) conference, this study highlights the potential of rapid initiation to transform the treatment of opioid use disorder.Data supporting the subcutaneous administration of SUBLOCADE to alternative injection sites including the thigh, upper arm, and buttocks vs current subcutaneous abdominal i
RICHMOND, Va., Nov. 7, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a letter from Oaktree Capital Management LP ("Oaktree") to the Board of Indivior. The Board has engaged actively with Oaktree in recent weeks on these topics, and remains open-minded about all proposals to enhance value creation. The Board is focused on acting in the best interests of all shareholders as we continue to execute on our strategy. Indivior looks forward to further engagement
Evidence demonstrates that SUBLOCADE supports long-term recovery from opioid use disorder (OUD) and is effective and safe.Publications highlight the importance of overcoming access barriers to long-acting injectable treatments for OUDRICHMOND, Va., Oct. 30, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV), in recognizing Substance Abuse Prevention Month, provides an update on key findings from the last year that demonstrate the importance of access to medications for the treatment of opioid use disorder (MOUD) and the effectiveness and safety of SUBLOCADE® in the treatment of OUD. These data add to the growing body of evidence that SUBLOCADE can improve outcomes, such as abstinence, rete
SLOUGH, United Kingdom and RICHMOND, Va., Oct. 24, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.
Conference Call Today at 8:00 AM US Eastern THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced preliminary Q3 2024 financial results and provided updated FY 2024 guidance. Group now sees lower than expected Q3 2024 and FY 2024 SUBLOCADE net revenue (NR) from a combination of faster initial adoption among treatment prov
PDUFA date set for February 7, 2025If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a single transmucosal buprenorphine dose; both of which address significant patient and healthcare provider unmet needs.RICHMOND, Va., Oct. 7, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the Prior Approval Supplement (PAS) for SUBLOCADE® (buprenorphine extended-release) injection submitted by Indivior, Inc. has been granted Priority Review designation by the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA)
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). Primary and Secondary End Points of the Study were Not Met Indivior Does Not Currently Expect to Exercise AEF0117 Option SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma's announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The
BARDA purchased OPVEE, a nalmefene opioid overdose reversal nasal sprayThrough BARDA's contract with Indivior, communities will be better equipped to respond to mass poisoning emergencies and address biosecurity threats involving synthetic opioidsRICHMOND, Va., Aug. 26, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced the first order of OPVEE® (nalmefene) nasal spray from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support its ongoing national preparedness efforts and help save lives during potential synthetic opioid overdo
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). Repurchases Under Current Program now Expected to be Completed by End of JulyRICHMOND, Va., July 25, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) ("Indivior" or the "Company"), a leading addiction treatment company, today announced that its Board of Directors has approved a new share repurchase program under which the Company will commence repurchasing Indivior's ordinary shares of $0.50 each (the "Ordinary Shares") for up to a maximum consideration of $100 million (
SLOUGH, UK and RICHMOND, Va., July 25, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending June 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com/mmc/p/jpgy4cd
Shares of Indivior PLC (NASDAQ:INDV) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program. Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million. Indivior shares jumped 14.5% to $12.46 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Psyence Biomedical Ltd. (NASDAQ:PBM) rose 157.4% to $1.00 in pre-market trading after the company
FY 2024 Guidance On July 9th, the Group updated its financial guidance for FY 2024 to reflect continued near-term adverse market dynamics impacting SUBLOCADE NR growth as well as the initial commercial adoption of OPVEE and the cessation of PERSERIS sales and marketing. The guidance set out is unchanged from the July 9th guidance. At the midpoint, the Group expects solid adjusted operating profit growth of 12% and adjusted operating margin expansion of approximately 100 bas
Repurchases Under Current Program now Expected to be Completed by End of July RICHMOND, Va., July 25, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) ("Indivior" or the "Company"), a leading addiction treatment company, today announced that its Board of Directors has approved a new share repurchase program under which the Company will commence repurchasing Indivior's ordinary shares of $0.50 each (the "Ordinary Shares") for up to a maximum consideration of $100 million (the "New Program"). The New Program will be carried out on an accelerated basis and is expected to be completed over the next six months, subject to compliance with applicable trading restrictions
Indivior (NASDAQ:INDV) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.14 by 214.29 percent. This is a 12.82 percent increase over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million by 1.00 percent. This is a 8.33 percent increase over sales of $276.00 million the same period last year.
Piper Sandler analyst David Amsellem initiates coverage on Indivior (NASDAQ:INDV) with a Overweight rating and announces Price Target of $22.
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 40 points on Tuesday. Shares of CrossFirst Bankshares, Inc. (NASDAQ:CFB) fell sharply in today's pre-market trading following second-quarter results. CrossFirst Bankshares reported quarterly earnings of 37 cents per share, according to data from Benzinga Pro. CrossFirst Bankshares shares dipped 12.3% to $13.98 in the pre-market trading session. Here are some big stocks recording losses in today's pre-market trading session. Applied Therapeutics, Inc. (NASDAQ:APLT) fell 11.8% to $5.24 in pre-market trading after gaining 7% on Monday. Owens & Minor, Inc. (NYSE:OMI) dipped 10.6% to $12.35 in pr
U.S. stock futures were mixed this morning, with the Dow futures gaining around 10 points on Friday. Shares of Wells Fargo & Company (NYSE:WFC) fell sharply in today's pre-market trading after the company posted second-quarter results. Wells Fargo earned a net income of $4.91 billion, down 1% year over year in the second quarter of 2024. The company reported a GAAP EPS of $1.33, beating the consensus of $1.29. Revenue rose 1% to $20.69 billion, according to data from Benzinga Pro. Wells Fargo shares fell 5.7% to $56.76 in the pre-market trading session. Here are some big stocks recording losses in today's pre-market trading session. NANO Nuclear Energy Inc. (NASDAQ:NNE) share
Craig-Hallum analyst Chase Knickerbocker maintains Indivior (NASDAQ:INDV) with a Buy and lowers the price target from $37 to $24.
U.S. stocks traded mixed toward the end of trading, with the S&P 500 gaining around 0.1% on Tuesday. The Dow traded down 0.05% to 39,323.7 while the NASDAQ rose 0.10% to 18,422.24. The S&P 500 also rose, gaining, 0.12% to 5,579.76. Check This Out: Nvidia To Rally Over 40%? Here Are 10 Top Analyst Forecasts For Tuesday Leading and Lagging SectorsFinancials shares jumped by 1.1% on Tuesday. In trading on Tuesday, materials shares fell by 0.6%. Top Headline Helen of Troy Limited (NASDAQ:HELE) reported soft first-quarter earnings and lowered its FY25 guidance. Equities Trading UP Soligenix, Inc. (NASDAQ:SNGX) shares shot up 379% to $9.59 after the
Piper Sandler initiated coverage of Indivior with a rating of Overweight and set a new price target of $22.00
Craig Hallum initiated coverage of Indivior with a rating of Buy and set a new price target of $37.00
Northland Capital initiated coverage of Indivior with a rating of Outperform and set a new price target of $35.00
SC 13G - INDIVIOR PLC (0001625297) (Subject)
SC 13G/A - INDIVIOR PLC (0001625297) (Subject)
SC 13D/A - INDIVIOR PLC (0001625297) (Subject)
SC 13D/A - INDIVIOR PLC (0001625297) (Subject)
SC 13D - INDIVIOR PLC (0001625297) (Subject)
SC 13G - INDIVIOR PLC (0001625297) (Subject)
SC 13G/A - INDIVIOR PLC (0001625297) (Subject)
SC 13D/A - INDIVIOR PLC (0001625297) (Subject)
SC 13G/A - INDIVIOR PLC (0001625297) (Subject)
SC 13G - INDIVIOR PLC (0001625297) (Subject)
SLOUGH, United Kingdom and RICHMOND, Va., Oct. 24, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.
Conference Call Today at 8:00 AM US Eastern THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced preliminary Q3 2024 financial results and provided updated FY 2024 guidance. Group now sees lower than expected Q3 2024 and FY 2024 SUBLOCADE net revenue (NR) from a combination of faster initial adoption among treatment prov
SLOUGH, UK and RICHMOND, Va., July 25, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending June 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com/mmc/p/jpgy4cd
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., July 9, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announces a business update encompassing the Group's outlook for Q2 and FY 2024 financial performance, its product portfolio and litigation. Indivior is: Updating Q2 net revenue (NR) expectations and FY 2024 guidance to reflect continued adverse market dynamics impacting near-ter
SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am EST)There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com/mm
SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced its financial results for the period ending December 31, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am EST)There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com/
SLOUGH, United Kingdom, and RICHMOND, Va., July 27, 2023 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced its financial results for the period ending June 30, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am EST)There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com/mmc
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)